Table 2.

Parameter estimates derived from the proportional odds model for the probability of experiencing any AE leading to dose interruption or dose reduction/drug withdrawal in patients with RR-DTC taking either lenvatinib or placebo

Parameter (units)	Point estimate	% RSE
B1	− 5.64	5.14
B2–B1	− 0.830	6.07
E max	6.55	11.4
EC50 (µg h/mL)	2.95	26.3
IIV (SD)	1.06	18.4

B1 baseline odds for experiencing an adverse event leading to dose interruption, B2–B1 baseline odds for experiencing an adverse event leading to dose reduction/withdrawal, E_max maximum effect of lenvatinib, EC₅₀ lenvatinib area under the concentration–time curve that results in 50% of E_max, IIV interindividual variability, RR-DTC radioiodine-refractory differentiated thyroid cancer, SD standard deviation, %RSE percent relative standard error of the estimate = SE/parameter estimate × 100